Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Immunotherapy Response Predicted by Machine Learning & Gut Microbiomes

Oncotarget

August 31, 2022
Researchers investigated common gut microbiome features of response among immunotherapy patients with different advanced-stage cancers. continue reading »

Epigenetics and Immunotherapy Combined Fights Rare Lymphoma

Oncotarget

August 23, 2022
In a new Oncotarget study, researchers assessed an epigenetic and immunotherapy treatment regimen among patients with blastic mantle cell lymphoma (bMCL). continue reading »

Oncotarget | Kinase Activity in Renal Cell Carcinoma, Benign Renal Tissue and in Response to Tyrosine Kinase Inhibitors

Oncotarget

August 17, 2022
PRESS RELEASE: A new research paper was published in Oncotarget on August 4, 2022, entitled, “Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors.” continue reading »

Oncotarget | Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma

News

August 11, 2022
PRESS RELEASE: A new research paper was published in Oncotarget on August 3, 2022, entitled, “Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma.” continue reading »

Oncotarget | A Novel Mechanism of Regulation of the Oncogenic Transcription Factor GLI3 by Toll-like Receptor Signaling

News

August 9, 2022
PRESS RELEASE: A new research paper was published in Oncotarget on August 3, 2022, entitled, “A novel mechanism of regulation of the oncogenic transcription factor GLI3 by toll-like receptor signaling.” continue reading »